{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:24:46Z","timestamp":1785896686373,"version":"3.56.0"},"reference-count":34,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Nutritional support for people with cystic fibrosis (PwCF) after the implementation of novel drug therapies is shifting from managing malnutrition through a high\u2010fat, high\u2010calorie diet to managing emerging incidences of obesity in this population. Additionally, dietary recommendations prescribed with elexacaftor\/tezacaftor\/ivacaftor (ETI) recommend taking this drug with a fat\u2010containing meal, which is variably interpreted by patients. This pilot and feasibility study was conducted to assess dietary fat intake and body composition on ETI plasma concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ten participants were enrolled in a 1:1 crossover design by dietary recommendations. To mimic recommendations made during routine clinical care, participants were instructed to consume either a general healthful diet (no more than 30% calories from fat) or a high\u2010fat diet (&gt;40% calories from fat) for a week before crossing over to the alternative diet.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This pilot study was acceptable to and feasible for study participants. Most participants increased fat intake calories when following a high\u2010fat diet. Body composition measurements showed a trending correlation between lean mass and fat\u2010free mass with ETI plasma concentrations. ETI compounds were quantified in plasma at 0\u2009h (prior to the ETI morning dose) and 6\u2009h after ingestion, and consuming a high\u2010fat diet did not significantly impact ETI concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Consuming a higher\u2010fat diet did not significantly impact ETI plasma concentrations, and all participants were in range for clinical effectiveness of ETI regardless of fat intake. This work provides vital pilot data to design larger studies to clarify dietary composition for optimal ETI exposure for PwCF on this therapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.4630","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:31:05Z","timestamp":1735000265000},"page":"920-926","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pilot and feasibility study of dietary composition with elexacaftor\u2010tezacaftor\u2010ivacaftor concentrations in people with cystic fibrosis"],"prefix":"10.1002","volume":"44","author":[{"given":"Natalie R.","family":"Rose","sequence":"first","affiliation":[{"name":"Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham  Birmingham Alabama USA"},{"name":"Department of Pediatrics, Division of Pulmonary and Sleep Medicine University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianna","family":"Bailey","sequence":"additional","affiliation":[{"name":"Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham  Birmingham Alabama USA"},{"name":"Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine University of Alabama at Birmingham  Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham  Birmingham Alabama USA"},{"name":"Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine University of Alabama at Birmingham  Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashritha R.","family":"Chalamalla","sequence":"additional","affiliation":[{"name":"Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham  Birmingham Alabama USA"},{"name":"Department of Pharmacology and Toxicology Division of Clinical Pharmacology  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[{"name":"Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham  Birmingham Alabama USA"},{"name":"Department of Pharmacology and Toxicology Division of Clinical Pharmacology  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0514-8536","authenticated-orcid":false,"given":"Jennifer S.","family":"Guimbellot","sequence":"additional","affiliation":[{"name":"Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham  Birmingham Alabama USA"},{"name":"Department of Pediatrics, Division of Pulmonary and Sleep Medicine University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043184"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jada.2008.02.020"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1158452"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2020.03.015"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25748"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2015.10.012"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.4.2104065"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2018.03.052"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2009.06.026"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14061216"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"e_1_2_10_14_1","unstructured":"Administration USFaD.Multi\u2010Discipline Review Application Number 212273Orig1s000. In: Research CfDEa editor.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf2019."},{"key":"e_1_2_10_15_1","unstructured":"Administration FaD.Drug Approval Package: Trikafta Food and Drug Administration: Food and Drug Administration.2019Available from:https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=212273"},{"key":"e_1_2_10_16_1","unstructured":"Administration FaD.Drug Approval Package: Kalydeco (ivacaftor): Food and Drug Administration.2012Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203188s000TOC.cfm"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.06.004"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.05.018"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2022.123518"},{"key":"e_1_2_10_20_1","unstructured":"Control CfD.Defining Adult Overweight and Obesity2022. Available from:https:\/\/www.cdc.gov\/obesity\/basics\/adult\u2010defining.html."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-020-00124-7"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu15030479"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23033"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2009.11.2074"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.112.051409"},{"key":"e_1_2_10_26_1","unstructured":"NEM.Cystic Fibrosis and Gene Modulator Therapy: Nutrition Considerations.2023Available from:https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0026\/1138904\/cf\u2010genemodulator.pdf"},{"key":"e_1_2_10_27_1","unstructured":"Group CCD.Nutrition and CFTR modulators.2023Available from:https:\/\/www.cysticfibrosis.ca\/blog\/nutrition\u2010and\u2010cftr\u2010modulators\/"},{"key":"e_1_2_10_28_1","unstructured":"Dietetics.DoNa Modulator therapy food guide.2023Available from:https:\/\/flipbooks.leedsth.nhs.uk\/LN004739.pdf"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2020.111124"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00203-2020"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26243"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03323-0"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.818726"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c160038"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.101870"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.4630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:05:08Z","timestamp":1761059108000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.4630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/phar.4630"],"URL":"https:\/\/doi.org\/10.1002\/phar.4630","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}